Facing looming patent cliffs, AstraZeneca has launched a restructuring initiative aimed at generating $1.5 billion in annual ...

A Pfizer joint venture in India that manufactures injectable chemotherapy drugs for U.S. cancer patients remains closed ...

As the commercial momentum behind Lilly’s tirzepatide franchise continues, analysts are increasingly turning their attention ...

Next-generation antibody-drug conjugates, bispecifics, radiopharmaceuticals, tyrosine kinase inhibitors ... Fierce provides a ...

Even as a wave of clinical trial wins bolsters its momentum, Merck & Co. is prioritizing ongoing pipeline and commercial ...

Even as AbbVie has demonstrated that Rinvoq and Skyrizi sales can more than make up for Humira's tumble over the patent cliff ...

For that indication, Rytelo is dosed at 7.1 mg/kg administered as an intravenous infusion every four weeks. Thrombocytopenia ...

Roughly one year into launch, Lenz Therapeutics, the maker of Vizz eye drops fo | In a massive overhaul of its operating ...

Pfizer’s Elrexfio has taken another step on its path to potential commercial momentum: The drugmaker just announced another ...

Several months after telegraphing a major antibody-drug conjugate manufacturing expansion in its native Switzerland, CDMO ...

As a cornerstone of Merck & Co.’s post-Keytruda oncology strategy, sac-TMT has cleared a clinical milestone. | As a ...

Pfizer’s Talzenna is now the first PARP inhibitor approved by the FDA to treat men with metastatic hormone-sensitive prostate ...